Cancer research at BESSY II: Binding Mechanisms of Therapeutic Substances Deciphered
The study is displayed on the cover of the journal Chemmedchem. © Chemmedchem/VCH Wiley
In tumor cells, the DNA is altered in comparison to normal body cells. How such changes can be prevented or inhibited is an exciting field of research with great relevance for the development of cancer treatments. An interdisciplinary team has now analysed the possible binding mechanisms in certain therapeutic substances from the tetrazole hydrazide group using protein crystallography at BESSY II.
Certain proteins such as human histone demethylases, including the KDM4 protein, play a role in the development of tumour cells. They bind to the DNA and modify it so that the cell can become cancerous. Therapeutic substances that are able to inhibit or even reverse such changes are of particular interest.
Biochemist Prof. Dr. Udo Heinemann from the Max Delbrück Centre in Berlin-Buch is investigating such processes. In cooperation with chemists led by Prof. Dr. Andreas Link from the University of Greifswald and the team led by Dr. Manfred Weiss at the HZB, he has now investigated how and where certain therapeutic substances from the tetrazole hydrazide group dock to these protein molecules and thus inhibit their harmful effect.
KDM4 protein crystals analysed
Link initially produced variations of tetrazole hydrazide substances. For structural analysis, crystals had to be grown from KDM4 proteins - a difficult task that Dr. Piotr Malecki and Manfred Weiss had taken on at the HZB. The KDM4 protein crystals were then soaked in a specific substance before being analyzed with strong X-rays on the MX beamlines of BESSY II. A refined analysis showed not only the three-dimensional architecture of the KDM4 protein, but also exactly where the active substances had docked to the KDM4 molecule.
"This class of substances has not yet been structurally investigated," explains Manfred Weiss. And Udo Heinemann from the MDC explains: "We will now evaluate where there are opportunities to dock even stronger within the 3D structure of the KDM4. Then we might also be able to develop drugs that inhibit the KDM4 even more and thus have the potential to become a therapeutic."
- New contact material boosts the efficiency of perovskite solar cellsA newly developed material for the electron contact improves the efficiency of single perovskite solar cells and perovskite/silicon tandem solar cells. The new material is based on a carborane molecule. It offers several advantages over the standard material C60, as shown by the study led by Steve Albrecht’s team. The new material has since been patented and is already commercially available.
- BESSY II: New sample environment allows glimpse into thermocatalytic processesA novel measurement cell allows, for the first time, soft and hard X-ray investigations under high pressures of up to 20 bar and temperatures of up to 400°C. This provides new insights into thermocatalytic processes, such as the Fischer-Tropsch synthesis for producing synthetic fuels. The development of the measurement cell is considered a significant achievement within the Care-O-Sene project.
- Precision interface chemistry pushes perovskite solar cells beyond 26% efficiencyAn international research collaboration has developed a new molecular strategy for controlling one of the most critical interfaces in perovskite solar cells. The resulting solar cells reached a power conversion efficiency of 26.19% in the n i p architecture, together with strong operational stability under prolonged illumination and elevated temperature. The results have been published in the Journal of the American Chemical Society.